NCIt related terms : Labetuzumab-SN-38 Immunoconjugate IMMU-130;
NCIt definition : An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5
humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor
SN-38, with antineoplastic activity. The monoclonal antibody moiety of labetuzumab
govitecan selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5),
which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization
and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the
activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication
and transcription and leading to tumor cell apoptosis.;
UNII : 8E3HI6QQ9J;
CAS number : 1469876-18-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1469876-18-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;